Eduardo Slatopolsky

Washington University in St. Louis — United States

Medicine · Health Sciences

86h-index23.5kcitations380works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Parathyroid Disorders and Treatments(206), Vitamin D Research Studies(105), Magnesium in Health and Disease(59), Bone health and treatments(53), Genetic Syndromes and Imprinting(45)

Publications378 total

Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease
Kidney International·2017· 22 citedOpen Access
Phosphate Toxicity in CKD: The Killer among Us
Clinical Journal of the American Society of Nephrology·2016· 143 citedOpen Access
The Noncalcemic Analogue of Vitamin D, 22-Oxacalcitriol, Suppresses Parathyroid Hormone Synthesis and Secretion
Contributions to nephrology·2015· 91 cited
Parathyroid Hormone Secretion: Perturbations in Chronic Renal Failure
Contributions to nephrology·2015· 6 cited
Do Vitamin D or Its Metabolites Directly Affect the Release of PTH?1
Contributions to nephrology·2015· 1 cited
Renal Osteodystrophy: Past and Future
Contributions to nephrology·2015· 7 cited
Impaired Skeletal Response to Parathyroid Hormone in Uremia: The Role of Phosphorus
Contributions to nephrology·2015· 1 cited
Differential expression and regulation of Klotho by paricalcitol in the kidney, parathyroid, and aorta of uremic rats
Kidney International·2015· 63 citedOpen Access
Should Monitoring of Fibroblast Growth Factor‐23 Levels in Dialysis Patients Be a Part of Routine Clinical Practice?
Seminars in Dialysis·2014
Targeting Parathyroid Hormone Levels in Dialysis Patients
Seminars in Dialysis·2014· 1 cited
Effects in renal and cardiac tissue from CKD rat model: antioxidant evaluation of treatment with the selective endothelin‐receptor antagonist atrasentan and the combination of atrasentan with the vitamin D receptor activator (paricalcitol), and the angiot (404.4)
The FASEB Journal·2014
Cardiac and Renal Effects of Atrasentan in Combination with Enalapril and Paricalcitol in Uremic Rats
Kidney & Blood Pressure Research·2014· 13 citedOpen Access
Phosphate restriction significantly reduces mortality in uremic rats with established vascular calcification
Kidney International·2013· 62 citedOpen Access
Clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of mineral and bone disorders in chronic kidney disease (CKD-MBD) in adults.
PubMed·2013· 31 cited
Vitamin D Therapy and Cardiac Function in Chronic Kidney Disease
JAMA·2012
FGF23 and PTH--double agents at the heart of CKD
Nephrology Dialysis Transplantation·2012· 71 citedOpen Access
Effect of combining an ACE inhibitor and a VDR activator on glomerulosclerosis, proteinuria, and renal oxidative stress in uremic rats
American Journal of Physiology-Renal Physiology·2011· 70 cited
Consenso en metabolismo óseo y mineral. Sociedad Argentina de Nefrología. Versión 2010. Capítulo VII: paratiroidectomía en la enfermedad renal crónica y un apéndice sobre biopsia ósea
Diálisis y Trasplante·2011
Consenso en metabolismo óseo y mineral. Sociedad Argentina de Nefrología. Versión 2010. Capítulo VI. Las calcificaciones vasculares en la enfermedad renal crónica con un apéndice sobre el diagnóstico de las calcificaciones vasculares
Diálisis y Trasplante·2011
The intact nephron hypothesis: the concept and its implications for phosphate management in CKD-related mineral and bone disorder
Kidney International·2011· 66 citedOpen Access
page 1 of 19Next →

Frequent Co-authors

Jane Finch(12), Adriana Dusso(11), Kévin Martin(8), James A. Delmez(5), Jeremiah J. Morrissey(5), Alex J. Brown(4), Cynthia S. Ritter(4), Neal S. Bricker(4), Silvia Lopez-Hilker(4), Steven K. Burke(4), Keith A. Hruska(4), Andrew J. Brown(4), Mario Cozzolino(4), Masahide Mizobuchi(3), Masashi Denda(3), Daniel R. Martin(3), Alex Brown(3), Steven L. Teitelbaum(3), Carol Weerts(2), Herschel R. Harter(2)